Sugi Predict

Sugi Predict / Compounds / SCHEMBL3314337

SCHEMBL3314337

SCHEMBL3314337

COC(=O)c1ncn([C@@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H]2OC(C)=O)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.55
▸ THRB P10828 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ CA1 P00915 13/20 0.47
▸ CA2 P00918 13/20 0.47
▸ CA9 Q16790 13/20 0.47
▸ CA12 O43570 10/20 0.47
▸ CA14 Q9ULX7 10/20 0.47
▸ PRKAB2 O43741 1/20 0.44
▸ PRKAG1 P54619 1/20 0.44
▸ PRKAA2 P54646 1/20 0.44
▸ PRKAA1 Q13131 1/20 0.44
▸ PRKAG3 Q9UGI9 1/20 0.44
▸ PRKAG2 Q9UGJ0 1/20 0.44
▸ PRKAB1 Q9Y478 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5718816 1.00 LMNA (0.55) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL13320635 1.00 LMNA (0.55) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL3314328 1.00 LMNA (0.55) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL5718815 1.00 LMNA (0.55) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL13352083 1.00 LMNA (0.55) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL7043671 0.90 LMNA (0.49) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL1110907 0.89 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL5566952 0.89 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL13614201 0.88 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1
SCHEMBL3313120 0.88 LMNA (0.52) LMNATHRBSMN1; SMN2HIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115322236-A Novel method for synthesizing ribavirin 启东东岳药业有限公司 2022-11-11 — — CN claimed
EP-1537134-B1 PROCESS FOR PRODUCING A RIBOFURANOSE HOFFMANN LA ROCHE (CH) 2006-04-05 — — EP claimed
US-6660854-B2 Reacting a 1,2,4-triazole-3-carboxylate and beta-D-ribo furanosyl-1,2,3,5-tetraacetate in the presence of a catalyst YUHAN CORPORATION (KR) 2003-12-09 — — US claimed
US-20230235330-A1 CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-07-27 — — US disclosed
US-20230235330-A1 CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-07-27 — — US disclosed
US-20230220386-A1 SIRNA CONJUGATE, DOUBLE-STRANDED SIRNA CONJUGATE, SALT THEREOF AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-07-13 — — US disclosed
CN-115322236-A Novel method for synthesizing ribavirin 启东东岳药业有限公司 2022-11-11 — — CN disclosed
CN-115322236-A Novel method for synthesizing ribavirin 启东东岳药业有限公司 2022-11-11 — — CN disclosed
CN-111647033-A Method for preparing ribavirin by one-pot method 济南明鑫制药股份有限公司 2020-09-11 — — CN disclosed
CN-109336937-B Preparation method of ribavirin 河南省科学院高新技术研究中心 2020-08-25 — — CN disclosed
US-8394935-B2 Method for producing furanose derivative API CORPORATION (JP) 2013-03-12 — — US disclosed
US-20030120064-A1 Processes for preparing beta-D-ribofuranose derivatives YUHAN CORPORATION (KR) 2003-06-26 — — US disclosed
WO-2003048157-A1 PROCESSES FOR PREPARING ¥Â-D-RIBOFURANOSE DERIVATIVES YUHAN CORPORATION (KR) 2003-06-12 — — WO disclosed
US-6573248-B2 Therapeutic agent for use in the treatment of tumors, infections, infestation and autoimmune disease ICN PHARMACEUTICALS, INC. 2003-06-03 — — US disclosed
EP-1132393-A1 L-Ribavirin and uses thereof ICN Pharmaceuticals, Inc. (US) 2001-09-12 — — EP disclosed
EP-1027359-A4 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS (US) 2001-07-25 — — EP disclosed
US-6130326-A Monocyclic L-Nucleosides, analogs and uses thereof ICN PHARMACEUTICALS, INC. (US) 2000-10-10 — — US disclosed
EP-1027359-A2 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN Pharmaceuticals, Inc. (US) 2000-08-16 — — EP disclosed
WO-1998016186-A2 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS, INC. (US) 1998-04-23 — — WO disclosed
US-RE29835-E PHARMACEUTICAL ICN PHARMACEUTICALS (US) 1978-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230220386-A1 SIRNA CONJUGATE, DOUBLE-STRANDED SIRNA CONJUGATE, SALT THEREOF AND APPLICATION THEREOF HAVCR2, SNRPE, SCARB1 LMNA 3104/4885THRB 2546/4885SMN1; SMN2 2890/4885
US-20230235330-A1 CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE HAVCR2, EIF2AK2, ASGR1 LMNA 1373/4885THRB 2004/4885SMN1; SMN2 4200/4885
US-20030120064-A1 Processes for preparing beta-D-ribofuranose derivatives UMPS, SBDS, SAMHD1 LMNA 2389/4885THRB 2580/4885SMN1; SMN2 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.